Array Technologies looks undervalued despite clean energy tailwinds. Click here to read more about the ARRY stock.
Exelixis, Inc.'s STELLAR-303 zanzalintinib data disappoints in colorectal cancer with an FDA decision due in December 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results